| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b4cb6f7c02cf308cc6b3701183d55b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c13193fe65025a46525ac2b48f75f12a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a339683e13a801fb88a3e76ac5b97c46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6826d39bf7e288ebf23e7339ceed9721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e34caa42903ecd9588cfbc1da44d58aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ceabb2ec048d4663d598ad4da154b15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36d7dfd99b132c6ed7c719d173ad16bd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B05D5-00 |
| filingDate |
2012-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a57ca6ce9a7980c21b50fee97480e51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e53f2af35ed3d5ccb8736e0ea08d019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1d6509aaed3bc7cc2ee7700f5230daf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0d74a82d6c3ed11f349484e327c5959 |
| publicationDate |
2013-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013011543-A1 |
| titleOfInvention |
Controlled release oxycodone compositions |
| abstract |
A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises forming spheroids comprising a spheronising agent and oxycodone or a salt thereof, and coating the spheroids with a controlled-release film coat. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9730885-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11096887-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017501086-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10485753-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017035225-A1 |
| priorityDate |
1992-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |